Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
Preparing for PrEP
- Details
- Category: HIV Prevention
- Published on Wednesday, 23 May 2012 00:00
- Written by Matt Sharp
PrEP (pre-exposure prophylaxis) is a new HIV prevention tool with great possibilities. Matt Sharp, who served as a community representative on the FDA panel that recommended approval of Truvada (tenofovir/emtricitabine) for PrEP, describes the vote and its implications.
FDA Advisory Committee Recommends Truvada for Prevention of HIV Sexual Transmission
- Details
- Category: HIV Prevention
- Published on Thursday, 10 May 2012 00:00
- Written by Liz Highleyman
On May 10, 2012, the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) decisively recommended approval of Truvada -- Gilead Sciences' tenofovir/emtricitabine combination pill -- for pre-exposure prophylaxis (PrEP) to prevent sexual transmission of HIV.
CROI 2012: Drug Levels Predict Efficacy in PrEP Trials, Highlighting Importance of Adherence
- Details
- Category: HIV Prevention
- Published on Thursday, 08 March 2012 00:00
- Written by Paul Dalton
Two analyses of PrEP studies presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle found that drug levels -- and by implication, adherence -- were strongly correlated with protection against HIV infection.
FDA Committee Will Consider Approval of Truvada for HIV PrEP this Thursday
- Details
- Category: HIV Prevention
- Published on Tuesday, 08 May 2012 00:00
- Written by Liz Highleyman
On May 10, 2012, the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will hear evidence regarding the use of the tenofovir/emtricitabine combination pill Truvada for pre-exposure prophylaxis (PrEP) to prevent HIV infection. Gilead Sciences requested approval of the expanded indication in December 2011.
CROI 2012: Final Partners PrEP Results Confirm Efficacy of Oral Antiretrovirals for HIV Prevention
- Details
- Category: HIV Prevention
- Published on Wednesday, 07 March 2012 00:00
- Written by Paul Dalton
Daily, oral pre-exposure prophylaxis (PrEP) using either tenofovir (Viread) or tenofovir/emtricitabine (Truvada) was highly effective at preventing HIV infection in a large study of serodiscordant heterosexual couples in sub-Saharan Africa, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
Web Design and Development by